CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Dupilumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03293030
NCT03293030Phase 4Completed
CompareCT.gov

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

University of California, San Francisco·interventional·Posted Sep 26, 2017·Updated Nov 14, 2025

In Brief

A Phase 4 clinical trial evaluating Dupilumab for Atopic Dermatitis and 3 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals, Sanofi

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 26, 2017
Enrollment StartOct 22, 2018
Primary CompletionFeb 23, 2023
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.8 years ago

Interventions

Dupilumabdrug

Dupilumab treatment